Bronchitis, Metastatic melanoma, Metastatic melanoma, Pneumonia, Rsv infection, Treatment of chronic hepatitis C virus.
Hypersensitivity. Pregnancy. Unstable cardiac disease, haemoglobinopathies. Severe hepatic impairment or decompensated.
Patients with extensive hepatic fibrosis, renal impairment, anaemias. Monitor CBC at the start of, and regularly during treatment. Ensure contraception during treatment and for at least 6 mth after treatment cessation in women and female partners of male patients. Increased risk of fatal and nonfatal MI in patients with anaemia.
Increased serum bilirubin and uric acid, haemolytic anaemia, anorexia, dyspepsia, nausea, irritability, dyspnoea, pharyngitis, skin rashes, pruritus and headache, abdominal cramps, fatigue, metallic taste. Increased thirst, GI complaints, mood changes, insomnia.